---
title: Melanoma
date: "2023-01-22"
enableToc: false
---

> [!info]
>
> ðŸŒ± ä¾†è‡ª: [[Huppert's Notes]]

# Melanoma #ðŸš§ æ–½å·¥ä¸­

### Melanoma

â€¢Â Â Â Epidemiology: 5th most common cancer in the United States. Risk factors: Older age, sun exposure, fair complexion, red/blonde hair, high nevi count, immunosuppression.

â€¢Â Â Â Clinical features: Atypical mole â€“ **ABCDE** criteria (**A**symmetry, irregular **B**order, **C**olor variation, **D**iameter â‰¥6 mm, **E**volution)

â€¢Â Â Â Diagnosis: Biopsy. Depth of invasion determines stage.

â€¢Â Â Â Treatment:

-Â Â Â Treatment depends on the stage:

**â€¢**Â Â Â Stage I/II: Wide local excision and sentinel lymph node biopsy is usually sufficient

**â€¢**Â Â Â Stage III: Surgery followed by adjuvant immunotherapy for 1 yr to reduce the risk of recurrence

**â€¢**Â Â Â Stage IV (metastatic): Recommend immunotherapy

-Â Â Â Systemic therapy options:

**â€¢**Â Â Â Immunotherapy: Anti-PD1 monotherapy (pembrolizumab or nivolumab) vs. anti-PD1/anti-CTLA4 combination therapy (niviolumab \+ ipilimumab)

**â€¢**Â Â Â Targeted therapy: BRAF inhibitor (vemurafenib, dabrafenib, encorafenib) \+ MEK inhibitor (cobimetinib, trametinib, binimetinib) if patient has BRAF V600E mutation

-Â Â Â Radiation: Can be used to treat symptomatic localized area of disease (e.g., brain metastases)

## Clinical presentation and workup
(NCCN Guidelines v1.2022)
â€¢ Suspicious skin lesion (ABCDE: asymm, border, color, diameter >6 mm, evolution) â†’ bx
â€¢ Staging: I & II = no regional/distant mets. III = regional LN âŠ• or in-transit/satellite mets. Ulceration & thickness confer substage within Iâ€“III. IV = distant mets.
â€¢ Prognosis: excellent if localized dis., â‰¤1 mm thickness. Varies widely stage IIIAâ€“IIID based on nodal burden (5yr OS 20â€“70%; ulceration, mitotic rate, & invasion depth predictive).
â€¢ Molecular diagnostics: check for BRAF V600E (present in ~50% of melanomas)

## Treatment

(NCCN Guidelines v1.2022; NEJM 2021;384:2229)
â€¢ Wide surgical excision + sentinel node mapping (unless in situ or low risk of node âŠ•).
If sentinel node âŠ•, nodal dissection vs. observation. No difference in survival w/ observation (Lancet Oncol 2016;17:757, NEJM 2017;376:2211).
â€¢ Checkpoint inhibitors (CPI = pembrolizumab, nivolumab, nivolumab/ipilimumab)
â€¢ BRAF/MEK inhibitors (dabrafenib/trametinib, vemurafenib/cobimetinib, encorafenib/binimetinib) if activating BRAF V600E mutation present
â€¢ Adjuvant for high-risk node âŠ• disease: CPI (â†‘ RFS, Lancet Onc 2020;21:1465 & JCO 2020;38:3925) or dabrafenib/trametinib (BRAF âŠ•, â†‘ OS, NEJM 2020;383:1139)
â€¢ Metastatic: CPI mono vs. dual (ipi+nivo a/w improved response rate especially for intracranial mets, NEJM 2018;379:722). Consider targeted Rx if BRAF âŠ•.
